From cosubstrate similarity to inhibitor diversity--inhibitors of ADP-ribosyltransferases from kinase inhibitor screening.

ADP-ribosyltransferases (ADP-RTs) use NAD(+) to transfer an ADP-ribosyl group to target proteins. Although some ADP-RTs are bacterial toxins only few inhibitors are known. Here we present the development of fluorescence-based assays and a focussed library screening using kinase inhibitors as a new approach towards inhibitors of ADP-RTs. Different screening setups were established using surrogate small molecule substrates or the quantitation of the cofactor NAD(+). Proof-of-principle screening experiments were performed using a kinase inhibitor library in order to target the NAD(+) binding pockets. This led to the discovery of structurally different lead inhibitors for the mono-ADP-ribosyltransferases Mosquitocidal toxin (MTX) from Bacillus sphaericus SSII-1, C3bot toxin from Clostridium botulinum and CDTa from Clostridium difficile. The interaction of the inhibitors with the toxin proteins was analyzed by means of docking and binding free energy calculations. Binding at the nicotinamide subpocket, which shows a significant difference in the three enzymes, is used to explain the selectivity of the identified inhibitors and offers an opportunity for further development of potent and selective inhibitors.

[1]  H. Mannherz,et al.  Photorhabdus luminescens Toxins ADP-Ribosylate Actin and RhoA to Force Actin Clustering , 2010, Science.

[2]  Kaixian Chen,et al.  A fluorometric assay of SIRT1 deacetylation activity through quantification of nicotinamide adenine dinucleotide. , 2009, Analytical biochemistry.

[3]  H. Kantarjian,et al.  Imatinib and beyond—exploring the full potential of targeted therapy for CML , 2009, Nature Reviews Clinical Oncology.

[4]  Simon Messner,et al.  Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites , 2009, Nucleic acids research.

[5]  A. Kazantsev,et al.  Biological and Potential Therapeutic Roles of Sirtuin Deacetylases , 2008, Cellular and Molecular Life Sciences.

[6]  G. Schulz,et al.  Structure and mode of action of a mosquitocidal holotoxin. , 2008, Journal of molecular biology.

[7]  A. Ashworth,et al.  Targeted therapy for cancer using PARP inhibitors. , 2008, Current opinion in pharmacology.

[8]  A. Pautsch,et al.  C3 exoenzymes, novel insights into structure and action of Rho-ADP-ribosylating toxins , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  C. Kunick,et al.  Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. , 2006, Journal of medicinal chemistry.

[10]  G. Schulz,et al.  Structure of the mosquitocidal toxin from Bacillus sphaericus. , 2006, Journal of molecular biology.

[11]  Brian J Eastwood,et al.  A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z' Factor, and Assay Variability Ratio , 2006, Journal of biomolecular screening.

[12]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[13]  D. Corda,et al.  Physiological relevance of the endogenous mono(ADP‐ribosyl)ation of cellular proteins , 2005, The FEBS journal.

[14]  M. Jung,et al.  In vitro assays for the determination of histone deacetylase activity. , 2005, Methods.

[15]  K. Aktories,et al.  Two-site autoinhibition of the ADP-ribosylating mosquitocidal toxin (MTX) from Bacillus sphaericus by its 70-kDa ricin-like binding domain. , 2004, Biochemistry.

[16]  K. Aktories,et al.  Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins , 2004, Microbiology and Molecular Biology Reviews.

[17]  P. Hergenrother,et al.  An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors. , 2004, Analytical biochemistry.

[18]  K. Aktories,et al.  Rho-modifying C3-like ADP-ribosyltransferases. , 2004, Reviews of physiology, biochemistry and pharmacology.

[19]  T. Sugimura,et al.  Mono(ADP-ribosyl)ation of DNA by apoptosis-inducing protein, pierisin. , 2002, Nucleic acids research. Supplement.

[20]  M. Rodnina,et al.  Inactivation of the Elongation Factor Tu by Mosquitocidal Toxin-Catalyzed Mono-ADP-Ribosylation , 2002, Applied and Environmental Microbiology.

[21]  K. Aktories,et al.  The ADP-ribosylating Mosquitocidal Toxin from Bacillus sphaericus , 2002, The Journal of Biological Chemistry.

[22]  K. Aktories,et al.  Characterization of the Enzymatic Component of the ADP-Ribosyltransferase Toxin CDTa from Clostridium difficile , 2001, Infection and Immunity.

[23]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[24]  V. D. Dyachenko,et al.  Synthesis of arylmethylenecyanothioacetamides in a Michael reaction , 1998 .

[25]  G. Corthier,et al.  Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196 , 1997, Infection and immunity.

[26]  M. Wilm,et al.  Clostridium novyi α-Toxin-catalyzed Incorporation of GlcNAc into Rho Subfamily Proteins* , 1996, The Journal of Biological Chemistry.

[27]  A. Hall,et al.  Microinjection of recombinant p21rho induces rapid changes in cell morphology , 1990, The Journal of cell biology.

[28]  M. Hagiwara,et al.  Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. , 1990, The Journal of biological chemistry.

[29]  S. Narumiya,et al.  Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. , 1989, The Journal of biological chemistry.

[30]  E. Rubin,et al.  Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain , 1988, Infection and immunity.

[31]  K. Aktories,et al.  Clostridium botulinum type C produces a novel ADP‐ribosyltransferase distinct from botulinum C2 toxin , 1987, FEBS letters.

[32]  D. T. Elmore,et al.  The behaviour of urokinase and porcine kidney cell plasminogen activator towards some synthetic peptides. , 1984, Thrombosis research.

[33]  Gill Dm,et al.  ADP-ribosylation of membrane proteins and activation of adenylate cyclase by cholera toxin in fat cell ghosts from euthyroid and hypothyroid rats , 1979 .

[34]  E. Kun,et al.  Covalent modification of proteins by metabolites of NAD+. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[35]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.